- Faron Pharmaceuticals said Wednesday its treatment to prevent vascular leakage and organ failures showed a 'substantial reduction' in death rates for patients suffering from acute respiratory distress syndrome, underscoring the efficacy of the treatment.

A clinical trial showed that acute respiratory distress syndrome (ARDS) patients receiving the company's Traumakine treatment and carrying the single nucleotide polymorphism (C/T) had a 5.7 times greater likelihood of survival at Day 28 compared with patients without the mutation, the company said.

No similar survival effect was seen for the C/T polymorphism in the placebo group, the company added.

'We have, and are continuing to build, a solid body of evidence which indicates that there is clearly a subgroup of patients for whom Traumakine treatment could potentially be very effective. The identification of these C/T patients is very easy with PCR-based analysis of a patient's DNA sample and provides a way to target this precise group of ARDS patients, representing around one third of all ARDS patients,' said Dr Markku Jalkanen, CEO of Faron.

'This finding has also allowed us to build further intellectual property for Traumakine as this association has not been previously reported. This protection has been filed and, if approved, could extend beyond 2040.'

At 10:27am: [LON:FARN] Faron Pharmaceuticals share price was +15.5p at 78.5p

Story provided by